IQVIA Holdings Inc (IQV)vsThermo Fisher Scientific Inc (TMO)
IQV
IQVIA Holdings Inc
$266.42
-1.12%
HEALTHCARE · Cap: $42.24B
TMO
Thermo Fisher Scientific Inc
$651.45
-1.04%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 173% more annual revenue ($46.34B vs $16.98B). TMO leads profitability with a 15.0% profit margin vs 8.1%. IQV appears more attractively valued with a PEG of 0.97. TMO earns a higher WallStSmart Score of 60/100 (C+).
IQV
Buy55
out of 100
Grade: C
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+12.0%
Fair Value
$201.30
Current Price
$266.42
$65.12 discount
Margin of Safety
-88.3%
Fair Value
$345.90
Current Price
$651.45
$305.55 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
IQV carries more volatility with a beta of 1.19 — expect wider price swings.
TMO is growing revenue faster at 10.5% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TMO scores higher overall (60/100 vs 55/100) and 10.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?